These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12778057)

  • 1. Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma.
    Zekri JM; Hough RE; Davies JM; Molife R; Hancock BW; Lorigan PC
    Br J Cancer; 2003 May; 88(9):1335-8. PubMed ID: 12778057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.
    Budman DR; Petroni GR; Johnson JL; Cooper MR; Schlossman DM; Barcos M; Peterson BA
    J Clin Oncol; 1997 Oct; 15(10):3275-9. PubMed ID: 9336365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
    Dourakis SP; Sevastianos VA; Alexopoulou A; Deutsch M; Stavrianeas N
    J Clin Oncol; 2002 Jul; 20(13):3030-2. PubMed ID: 12089234
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
    Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
    Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
    Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
    Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
    Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.
    Lenzi R; Yalcin S; Evans DB; Abbruzzese JL
    Cancer Invest; 2002; 20(4):464-72. PubMed ID: 12094541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.
    Kaye SB; Piccart M; Aapro M; Francis P; Kavanagh J
    Eur J Cancer; 1997 Nov; 33(13):2167-70. PubMed ID: 9470802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
    Schmidinger M; Budinsky AC; Wenzel C; Locker GJ; Pluschnig U; Brodowicz T; Kubista E; Maca S; Zabernigg A; Ilsinger P; Seewann L; Hojas S; Blach M; Zielinski CC; Steger GG
    Cancer Chemother Pharmacol; 2001; 47(1):57-62. PubMed ID: 11221963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
    Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
    Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of docetaxel in advanced non-small cell lung cancer.
    Saarinen A; Jekunen A; Halme M; Pyrhönen S; Tamminen K; Boyer R; Roubille N; Mattson K
    Anticancer Drugs; 1996 Nov; 7(8):890-2. PubMed ID: 8991195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer.
    Latreille J; Cormier Y; Martins H; Goss G; Fisher B; Eisenhauer EA
    Invest New Drugs; 1996; 13(4):343-5. PubMed ID: 8824354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel in patients with anthracycline-resistant advanced breast cancer.
    Vici P; Belli F; Di Lauro L; Amodio A; Conti F; Foggi P; Gionfra T; Morelli MF; Botti C; Ferraironi A; Lopez M
    Oncology; 2001; 60(1):60-5. PubMed ID: 11150910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
    Sanson M; Napolitano M; Yaya R; Keime-Guibert F; Broët P; Hoang-Xuan K; Delattre JY
    J Neurooncol; 2000 Dec; 50(3):245-9. PubMed ID: 11263504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
    de Wit R; Kruit WH; Stoter G; de Boer M; Kerger J; Verweij J
    Br J Cancer; 1998 Nov; 78(10):1342-5. PubMed ID: 9823976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.
    Alexopoulos K; Kouroussis C; Androulakis N; Papadakis E; Vaslamatzis M; Kakolyris S; Samelis G; Patila E; Vossos A; Samantas E; Georgoulias V
    Cancer Chemother Pharmacol; 1999; 43(3):257-62. PubMed ID: 9923557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
    Kruijtzer CMF ; Verweij J; Schellens JH; Beijnen JH; Pronk L; Bo M; Lustig V; van Tinteren H; Mackay M; Ten Bokkel Huinink WW
    Anticancer Drugs; 2000 Apr; 11(4):249-55. PubMed ID: 10898539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
    Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
    Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.
    Kavanagh JJ; Kudelka AP; de Leon CG; Tresukosol D; Hord M; Finnegan MB; Kim EE; Varma D; Forman A; Cohen P; Edwards CL; Freedman RS; Verschraegen CF
    Clin Cancer Res; 1996 May; 2(5):837-42. PubMed ID: 9816238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.